Sugi Predict

Sugi Predict / Compounds / SCHEMBL5436181

SCHEMBL5436181

SCHEMBL5436181

N=C(N)NC(=O)C=CC=Cc1ccccc1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 1/20 0.49
▸ LY96 Q9Y6Y9 1/20 0.46
▸ BCHE P06276 1/20 0.43
▸ HDAC8 Q9BY41 6/20 0.43
▸ HDAC6 Q9UBN7 6/20 0.43
▸ HDAC1 Q13547 5/20 0.43
▸ HDAC3 O15379 4/20 0.43
▸ HDAC4 P56524 4/20 0.43
▸ HDAC7 Q8WUI4 4/20 0.43
▸ HDAC2 Q92769 4/20 0.43
▸ HDAC10 Q969S8 4/20 0.43
▸ HDAC11 Q96DB2 4/20 0.43
▸ HDAC9 Q9UKV0 4/20 0.43
▸ HDAC5 Q9UQL6 4/20 0.43
▸ EGFR P00533 2/20 0.39
▸ MAOB P27338 2/20 0.37
▸ HTT P42858 1/20 0.37
▸ NFE2L2 Q16236 1/20 0.37
▸ KMT2A Q03164 2/20 0.36
▸ MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30071732 1.00 HSD11B1 (0.49) HSD11B1LY96BCHEHDAC8HDAC6
SCHEMBL5670323 1.00 HSD11B1 (0.49) HSD11B1LY96BCHEHDAC8HDAC6
SCHEMBL30071642 0.90 HSD11B1 (0.57) HSD11B1LY96BCHEHDAC8HDAC6
SCHEMBL5423686 0.90 HSD11B1 (0.57) HSD11B1LY96BCHEHDAC8HDAC6
SCHEMBL5423682 0.90 HSD11B1 (0.57) HSD11B1LY96BCHEHDAC8HDAC6
SCHEMBL5435312 0.79 HDAC3 (0.65) HDAC8HDAC6HDAC1HDAC3HDAC4
SCHEMBL5435310 0.79 HDAC3 (0.65) HDAC8HDAC6HDAC1HDAC3HDAC4
SCHEMBL5427020 0.75 MAOB (0.56) HDAC8HDAC6HDAC1HDAC3HDAC4
SCHEMBL5671341 0.75 MAOB (0.56) HDAC8HDAC6HDAC1HDAC3HDAC4
SCHEMBL5436185 0.74 HSD11B1 (0.51) HSD11B1LY96BCHEHDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2617709-B1 Guanidine derivatives as antiviral agents BIOTRON LTD (AU) 2022-11-16 — — EP claimed
US-11192863-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2021-12-07 — — US claimed
US-10472332-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2019-11-12 — — US claimed
US-20170260147-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2017-09-14 — — US claimed
US-20150313909-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2015-11-05 — — US claimed
US-20130035328-A1 ANTIVIRAL COMPOUNDS AND METHODS GAGE PETER WILLIAM (AU) 2013-02-07 — — US claimed
US-20070099968-A1 Antiviral compounds and methods BIOTRON LIMITED (AU) 2007-05-03 — — US claimed
EP-1646371-A2 ANTIVIRAL COMPOUNDS AND METHODS Biotron Limited (AU) 2006-04-19 — — EP claimed
WO-2004112687-A2 ANTIVIRAL ACYLGUANIDINE COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2004-12-29 — — WO claimed
EP-2617709-B1 Guanidine derivatives as antiviral agents BIOTRON LTD (AU) 2022-11-16 — — EP disclosed
US-11192863-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2021-12-07 — — US disclosed
US-10472332-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2019-11-12 — — US disclosed
EP-2826770-B1 ACYLGUANIDINE COMPOUNDS WITH ANTIVIRAL ACTIVITY BIOTRON LTD (AU) 2018-09-12 — — EP disclosed
US-20170260147-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2017-09-14 — — US disclosed
EP-1902017-B1 Antiviral acylguanidine compounds BIOTRON LTD (AU) 2014-03-26 — — EP disclosed
EP-2617709-A1 Guanidine derivatives as antiviral agents Biotron Limited (AU) 2013-07-24 — — EP disclosed
US-20130035328-A1 ANTIVIRAL COMPOUNDS AND METHODS GAGE PETER WILLIAM (AU) 2013-02-07 — — US disclosed
US-20070099968-A1 Antiviral compounds and methods BIOTRON LIMITED (AU) 2007-05-03 — — US disclosed
EP-1646371-A2 ANTIVIRAL COMPOUNDS AND METHODS Biotron Limited (AU) 2006-04-19 — — EP disclosed
WO-2004112687-A2 ANTIVIRAL ACYLGUANIDINE COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2004-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192863-B2 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 HSD11B1 2826/4885LY96 830/4885BCHE 2235/4885
US-10472332-B2 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 HSD11B1 2826/4885LY96 830/4885BCHE 2235/4885
US-20070099968-A1 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 HSD11B1 2483/4885LY96 1249/4885BCHE 1540/4885
US-20170260147-A1 ANTIVIRAL COMPOUNDS AND METHODS MAVS, ZC3HAV1, EIF2AK2 HSD11B1 2826/4885LY96 830/4885BCHE 2235/4885
US-20130035328-A1 ANTIVIRAL COMPOUNDS AND METHODS ZC3HAV1, MAVS, EIF2AK2 HSD11B1 2829/4885LY96 1013/4885BCHE 1951/4885
US-20150313909-A1 ANTIVIRAL COMPOUNDS AND METHODS ZC3HAV1, MAVS, EIF2AK2 HSD11B1 2829/4885LY96 1013/4885BCHE 1951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback